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Introduction
Fabry disease is an X-linked lysosomal storage disease, re-
sulting from a deficiency of the enzyme α-galactosidase
A and subsequent cellular storage of the enzyme substrate
globotriaosylceramide (Gb3) [1]. Estimates of the incidence
of Fabry disease vary markedly, from 1:<5000 male births
in a newborn screening study in Italy [2] to 1:117 000 male
births in Australia [3] and 1:833 000 male births in north-
ern Portugal [4]. In general, hemizygous males are more
severely affected than heterozygous females. In males, life
expectancy is reduced by an average of 20 years [5] and
in females by 15 years [6]. Although males tend to suf-
fer symptoms earlier than females, both boys and girls can
be affected from an early age [7]. Death usually occurs
due to renal, cardiovascular or cerebrovascular complica-
tions [5,6,8], with renal dysfunction being the main cause
of death in men before the development of renal failure
requiring dialysis and transplantation [9].
As enzyme replacement therapy (ERT) has recently be-
come available, it is important to recognize the signs and
symptoms of Fabry disease so that early treatment can be
started before irreversible organ damage occurs. This short
review outlines the renal manifestations of Fabry disease
and the results of ERT.
Clinical features
Natural history
Urinary concentration defects, despite being rare, may be
the earliest manifestation of renal dysfunction, and are
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responsible for polyuria and nycturia. Otherwise, the first
clinical manifestation of Fabry-related renal disease is
proteinuria. In their review of the natural history of renal
involvement in 105 male patients, Branton et al. found that
50% of patients presented with proteinuria by 35 years
of age and 100% by 52 years of age [9]. In patients
with Fabry nephropathy in FOS—the Fabry Outcome
Survey—the usual level of proteinuria is 0.5–2.0 g per 24 h.
True nephrotic syndrome is not frequent, even in patients
who have proteinuria in the nephrotic range [9]. Micro-
scopic haematuria is present in 30% of patients.
Chronic renal insufficiency (CRI) develops concomi-
tantly to proteinuria in the majority of male patients.
Branton et al. found that 50% of male patients presented
with CRI by 42 years of age. After the development of
CRI, there was a rapid decline in glomerular filtration rate
(GFR) of 12.2ml/min/year (range, 3–34ml/min/year), lead-
ing to end-stage renal disease (ESRD) after further 4.1 years
[9]. It is of note that only 18 of the 105 patients studied
had received angiotensin antagonist therapy at any time
(6 for hypertension alone, 1 for hypotension and protein-
uria, 5 for hypertension with CRI, 3 with proteinuria alone,
1 with congestive heart failure, 2 for reasons unknown)
and 11 of the 31 hypertensive patients had medically con-
trolled hypertension. Unpublished data from the Necker
Hospital in Paris suggest that the rate of decrease in GFR
may be slower in patients with Fabry disease who are re-
ceiving these nephroprotective measures as standard. It is
interesting that the progressive decline in GFR reported
by Branton and colleagues is similar to that seen in un-
treated diabetic nephropathy and occurs more rapidly than
in primary glomerulonephritis [10]. Both these diseases
are multisystemic and their nephropathies are caused ini-
tially by metabolic deposits—Gb3 in Fabry disease and
end-glycosylation products in diabetes. They may both
progress in a similar manner to chronic non-diabetic pro-
teinuric nephropathies via a common pathophysiological
pathway that is relatively independent of the initial renal in-
sult [11,12]. Contrary to patients with diabetes type I or II,
nearly all male patients with Fabry disease will develop
CRI during their lifetime. Hypertension is observed in
60% of patients with diabetic nephropathy and, if untreated,
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contributes to the progression of CRI [13]. Similarly, hyper-
tension has been found in 57% of men and 47% of women
with Fabry disease [14]. Finally, as for other monogenic
diseases, there is a remarkable variability in the rate of pro-
gression of nephropathy [15] that may be partly explained
by the role of modifier genes.
A renal biopsy may be used to diagnose Fabry disease in
patients with renal symptoms or to follow treatment with
ERT; however, diagnosis is often based on non-renal man-
ifestations [9]. Such manifestations include characteris-
tic skin lesions (angiokeratomas), acroparaesthesia, cornea
verticillata and left ventricular hypertrophy. A diagnosis
may also be made as a result of a family history of the dis-
ease. Confirmation of the diagnosis by measurement of the
plasma and leukocyte activity of α-galactosidase A in male
patients and genetic analysis in female patients is necessary.
Because Fabry disease is a rare, often unrecognized dis-
ease, the nephropathy is often already present by the time
diagnosis is made. For example, Branton et al. reported
that the mean age at diagnosis of Fabry disease in 44 pa-
tients was 16 ± 13 years, even though these patients had a
known family history. The age at diagnosis of 50 patients
without a known family history of Fabry disease was even
higher, at 28 ± 12 years, despite signs of the disease being
apparent well before diagnosis. Other studies and data
from FOS have also highlighted the delay between onset of
symptoms in childhood and diagnosis [5,7], pointing to the
need for physicians to rediscover the disease because of the
availability of ERT and early nephroprotective measures.
Other newly recognized aspects of Fabry nephropathy
have been reported recently. In a study of male children
with Fabry disease, Ries et al. found that 20 out of 25
patients had microalbuminuria and that 13 out of 25 had
an estimated GFR (using the Schwartz formula) above 140
ml/min, suggestive of hyperfiltration, a well-known risk
factor for glomerular injury that is responsible for increased
glomerular permeability to albumin [16].
Moreover, another recent study has shown that there
may already be evidence of CRI (estimated GFR of 60–
89 ml/min/1.73 m2) in some untreated children with Fabry
disease (n = 2/24) [17]. There is clear evidence that the
burden of Fabry nephropathy is already present in boys
with Fabry disease and probably starts with a (presumed)
silent phase, including hyperfiltration and/or microalbu-
minuria (stage II Fabry nephropathy; Table 1), which
progresses to overt proteinuria, CRI and, finally, ESRD, an
evolution closely resembling that seen in diabetic nephropa-
thy (Figure 1) [9]. Renoprotective treatment in patients
with Fabry disease should therefore be the same as that for
patients with type 1 and type 2 diabetes; i.e. these patients
should be treated during the silent phase of the disease to
slow, halt or even reverse the pathological changes that lead
to renal failure. The literature suggests that the course of
kidney disease is generally less severe in females; however,
some of them will progress to ESRD before the age of
40 years [18].
Pathophysiology
Progressive accumulation of Gb3 in the kidney results
in mesangial expansion and glomerulosclerosis, tubular
Fig. 1. The interrelationships between functional and morphological
markers in diabetic and Fabry nephropathy. Great similarities are found
between these conditions.
atrophy and interstitial fibrosis—non-specific anomalies
seen in most glomerular diseases and diabetic nephropathy
[19]. Vascular injury due to Gb3 deposition in the capil-
laries and arterial wall probably plays a central role in the
loss of nephrons, via ischaemic degenerative alterations.
As such, Fabry nephropathy is not only a disease associated
with deposition, it should also be considered a vascular dis-
ease, like diabetic nephropathy. However, it is likely that
other mechanisms, secondary to the progressive accumula-
tion of Gb3, are also involved in the pathogenesis of Fabry
nephropathy.
In patients with Fabry nephropathy, all types of renal
glomerular cells show lipid inclusions—as do the endothe-
lial and smooth muscle cells of renal vessels, epithelial
cells of the proximal tubule, loop of Henle, distal tubule
and interstitial cells [20]. Podocytes, in particular, contain
high levels of glycosphingolipid deposits early during
childhood, although it remains unclear whether the
glomerular filtration barrier is physically compromised,
as many women with Fabry disease have podocyte de-
posits without proteinuria throughout their life. Neverthe-
less, GFR declines over time, mainly due to ischaemic
degenerative changes provoked by vascular involvement
and progressive expansion of the mesangial matrix, which
occurs concomitant to the development of overt protein-
uria. Expansion of the mesangial matrix, in turn, leads to
thickening of the glomerular basement membrane and
ultimately to glomerulosclerosis [21]. In order to evaluate
the renal response to ERT, a scoring system for chronic
glomerular, vascular, tubular and interstitial alterations is
needed.
A series of guidelines for the recognition, evaluation
and surveillance of disease-associated morbidities and
therapeutic strategies for Fabry disease have been pro-
posed by an international panel of experts [22]. These
guidelines recommend that evaluation of kidney func-
tion, including estimates of GFR and proteinuria, should
be carried out in every patient with Fabry disease.
Furthermore, they note that a multidisciplinary approach
to treatment of Fabry disease is required, necessitating
cooperation and participation between geneticists,
nephrologists, cardiologists, neurologists and other
clinicians.
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Table 1. Proposed stages of progression of Fabry nephropathy in male patients
Time of evolution
(years) Urinanalysis Level of GFR Pathology Efficacy of ERT
Stage I 0–5 Normal <90 ml/min<140 ml/min Gb3 deposits mainly in
podocytes and capillaries +/++
Incomplete clearance of
deposits after 5 years
Stage II 6–19 Microalbuminuria
(30–300 mg/day)
>140 ml/min Gb3 deposits ++/+++
Mesangial expansion +
Possible reversibility of
hyperfiltration; no data on
microalbuminuria Point of
no return?
Stage III 20–29 Overt proteinuria
(>300 mg/day)
>60 ml/min<140 ml/min Gb3 deposits ++/+++
Mesangial expansion ++
Glomerulosclerosis +/++
Tubular atrophy + Arterial
remodelling +/++
No significant effect on
proteinuria Stabilization of
GFR in the majority of
patients










No stabilization but slows the
rate of progression of
chronic renal insufficiency
CRI, chronic renal insufficiency; ESRD, end-stage renal disease; ERT, enzyme replacement therapy; Gb3, globotriaosylceramide; GFR, glomerular
filtration rate; +, mild; ++, moderate; +++, severe.
Treatment for Fabry nephropathy
Transplantation
Kidney transplantation, with cadaveric or living donor, is
considered the optimal therapy for ESRD in suitable pa-
tients. A recent analysis of the United States Renal Data
System (USRDS) database found 93 incident cases of
Fabry-related ESRD, where patients underwent renal trans-
plantation between 1988 and 1998 [23]. One-, five-, and
ten-year graft survival in recipients with Fabry disease
(91%, 76% and 56%, respectively) was statistically similar
to rates of graft survival in patients without Fabry disease
(88%, 67% and 49%, respectively). Furthermore, survival
rate and the risk of cardiovascular death in untreated (i.e.
not receiving ERT) patients with Fabry disease were not
statistically different from those of other renal transplant
recipients, with cumulative 10-year Kaplan–Meier patient
survival estimate being 67% in recipients with untreated
Fabry disease and 63% in controls. Despite these surpris-
ingly good results, which may be due to the selection of
excellent candidates for transplantation for the study, trans-
planted patients should also be treated with ERT, as renal
transplantation does not correct the underlying metabolic
deficit in other organs.
Enzyme replacement therapy
The introduction of ERT with recombinant α-galactosidase
A offers the prospect of altering the natural course of Fabry
disease. It is still important, however, to systematically con-
sider adjunctive renoprotective treatments (ACE inhibitors
and/or ARBs) that are known to be effective in slowing
disease progression in other chronic proteinuric kidney dis-
eases [24].
Two forms of α-galactosidase A have been approved in
Europe for use in patients with Fabry disease: agalsidase
alfa (Replagal R©; Shire Human Genetic Therapies, Boston,
MA, USA) and agalsidase beta (Fabrazyme R©; Genzyme
Corp., Cambridge, MA, USA). Agalsidase alfa is produced
in a continuous human cell line. It is administered as an
intravenous (i.v.) infusion over 40min at a dose of 0.2mg/kg
body weight every 2 weeks. Agasidase beta is produced
in Chinese hamster ovary (CHO) cells and is a chimeric
protein. It is given as an i.v. infusion over ∼4.7 h for a
70 kg patient at a dose of 1.0 mg/kg body weight every
2 weeks. These recommended doses for agalsidase alfa
and agalsidase beta were determined using dose-finding
studies. In the case of agalsidase alfa, a range of doses
(0.007–0.1 mg/kg) were administered to male patients with
Fabry disease (n = 2 for each dose) [25]. Pharmacokinetic
profiles and tolerability were comparable at all doses and
levels of urinary sediment Gb3 were decreased by similar
amounts [26]. Based on these observations, a dose of 0.2
mg/kg every 2 weeks was tested in longer-term studies and
was found to be well tolerated in patients with Fabry disease
[27]. In the case of agalsidase beta, the effects of 0.3, 1.0
and 3.0 mg/kg once every 2 weeks and 1.0 and 3.0 mg/kg
once every 2 days were evaluated [25]. A reduction of Gb3
was observed in the kidney, heart, skin and plasma at all
doses. PlasmaGb3 was cleared in a dose-dependentmanner,
but was less consistent at the dose of 0.3 mg/kg. Infusion-
associated reactions were also dose dependent [25].
The efficacy and, possibly, the safety of ERT critically
depend on the infused therapeutic enzyme being recog-
nized as an endogenous compound and transported to its
site of activity—the lysosome. Enzymes produced for ERT
should therefore resemble as closely as possible their nat-
ural counterparts, including the pattern of glycosylation.
As glycosylation patterns are species- and cell-type spe-
cific, it has been suggested that this may have important
implications in the production of recombinant therapeutic
proteins [28]. While separate clinical studies have demon-
strated the efficacy of both agalsidase alfa and agalsidase
beta in slowing the progression of Fabry disease [27,29],
there are limited data on the comparative efficacy and toler-
ability of these preparations when tested in parallel. In the
only clinical head-to-head comparison of agalsidase alfa
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and agalsidase beta (both at 0.2 mg/kg EOW), the clini-
cal potency of these preparations was found to be broadly
similar [30]. The one difference reported between the two
preparations being that among patients with elevated uri-
nary Gb3 levels at baseline, mean levels were significantly
reduced in the agalsidase alfa group (P = 0.04) but not the
agalsidase beta group (P= 0.66). However, due to the small
number of patients enrolled in this study, inconsistencies in
the collection of baseline and follow-up measurements and
the observation by the authors that damage in this severely
affected older population group will probably not respond
to therapy, the relative efficacies of these drugs remains
incompletely defined.
As alreadymentioned, variation in glycosylation patterns
between agalsidase alfa and agalsidase beta may have im-
plications for the long-term safety of ERT in patients with
Fabry disease. Differences in antibody formation have been
reported between theseCHO- and human fibroblast-derived
enzymes. Data from long-term clinical trials using the ap-
proved doses suggest that IgG antibodies develop in a higher
proportion of patients receiving agalsidase beta (89.7%)
than agalsidase alfa (56%) [31,32]; however, differences in
methods of antibody detection make comparison difficult.
Antibody formation has also been assessed in two head-
to-head trials; however, these studies were on small patient
groups and have included a lower dose of agalsidase beta
than typically employed clinically, making conclusions lim-
ited [30,33]. In the first study, IgG antibodies were reported
in 11 out of 18 patients (in 4 out of 7 patients on 0.2 mg/kg
agalsidase alfa EOW, 4 out of 6 patients on 0.2 mg/kg
agalsidase beta EOW, 3 out of 5 patients on 1.0 mg/kg agal-
sidase beta EOW) during the first 6–12months of treatment
and all antibodies exhibited neutralizing capacities in vitro
and there was complete cross-reactivity [33]. In a second
24-month study comparing both treatments at the same dose
(0.2 mg/kg EOW), antibodies developed in four out of eight
patients on agalsidase alfa and six out of eight patients on
agalsidase beta [30]. While these data should be interpreted
with caution, even when receiving a lower dose than typ-
ically given clinically, a greater proportion of patients on
agalsidase beta appear to develop antibodies. Furthermore,
IgE antibodies have been reported after infusion of agalsi-
dase beta [32,34], but not so far in patients given agalsidase
alfa.
Several studies have reported that IgG antibody for-
mation interferes with urinary and plasma Gb3 clearance
[30,31,33,35–37]; however, the relationship between anti-
bodies, Gb3 levels and clinical response is far from clear.
The elevated levels of urinary and plasma Gb3 reported
in patients with IgG antibodies suggest that these antibod-
ies may have a neutralizing effect. Consistent with these
reports, studies of both enzymes in small patient groups
have reported in vitro inhibition of serum enzyme activity in
patients with IgG antibodies [33,35]. It has been suggested
that higher doses may be needed in patients with antibodies
to ensure delivery to the target tissues [36]; however, this
has yet to be thoroughly evaluated and it must be remem-
bered that in vitro enzyme inhibition does not necessarily
imply a loss of efficacy at the level of the lysosome.
It is also important to note that clinical improvements
have been reported in patients with IgG antibodies and
elevated Gb3 levels. In the recent head-to-head study,
despite the failure of treatment with either product to clear
urinary and plasma Gb3 in antibody positive patients, the
induction of antibodies did not correlate with the occur-
rence of treatment failure (defined as progression of renal
disease, cardiac disease or occurrence of a new cerebrovas-
cular accident/lacunar infarction) [30]. In the clinical trial
by Schiffmann et al., the presence or absence of persistently
positive IgG antibodies against agalsidase alfa did not ap-
pear to correlate with the magnitude or direction of changes
in estimated GFR in individual patients [31]. In fact, the
authors report that there were patients with persistent anti-
bodies who demonstrated improvement in estimated GFR.
Such data show that treatment may be clinically effective
despite a failure to effectively clear Gb3, calling into ques-
tion the usefulness of Gb3 for monitoring the response to
treatment. It is clear that well-controlled studies using com-
parable methodology are needed to address these issues.
Clinical efficacy
The original studies of the efficacy of agalsidase alfa and
agalsidase betawere carried out bySchiffmann et al. [26,27]
and Eng et al. [25,29], respectively. Schiffmann et al.
undertook a double-blind, randomized, placebo-controlled
study of agalsidase alfa, administered for 6 months
to 26 patients with Fabry disease. This was followed by
a 12-month open-label maintenance study of all patients
completing the placebo-controlled study [26,27]. Statisti-
cally significant reductions in neuropathic pain (P = 0.02),
the primary endpoint of the study, were accompanied by
a statistically significant improvement in creatinine clear-
ance compared with placebo (P= 0.02). This improvement
in renal function was maintained over a further 12-month
follow-up in patients treated with agalsidase alfa, and renal
function was stabilized in the patients who were initially
given placebo and then switched to ERT.
In linewith the stabilization in renal function, histopatho-
logical assessments showed a 21% increase in the propor-
tion of normal glomeruli and a 33% decrease in mesangial
widening following agalsidase alfa treatment. In contrast,
the placebo-treated group saw a 27%decrease in the propor-
tion of normal glomeruli and a 69% increase in mesangial
widening. Furthermore, a significant decrease in glycol-
ipid deposits in vascular endothelial cells and a significant
fall in Gb3 concentrations in plasma and urinary sediment
were seen in patients treated with agalsidase alfa com-
pared with those given placebo at the end of the 12-month
follow-up study. Thesemetabolic improvementsweremain-
tained throughout 48 months of treatment with agalsidase
alfa [31]. In addition, this study showed that long-term
treatment appeared to stabilize kidney function in patients
with mild-to-moderate chronic kidney disease at baseline
(GFR ≥ 60 ml/min/1.73 m2), and to slow the decline in
renal function in the subgroup of adult male patients with
an estimated GFR of 30–59 ml/min/1.73 m2 at baseline
compared with historical controls [9].
Eng et al. conducted a double-blind, randomized,
placebo-controlled study in 58male patients with Fabry dis-
ease who were treated with agalsidase beta every 2 weeks
for 20 weeks. The primary endpoint of the study was
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clearance of Gb3 deposits in interstitial capillary endothe-
lial cells [29]. Clearance was achieved in 20 of the 29
patients receiving active therapy compared with 0 out of 29
patients given placebo. Further histopathological analysis
of kidney biopsy samples from 48 of the 58 patients showed
nevertheless that Gb3 clearance in podocytes and the distal
tubular epithelium was limited, compared with other renal
cell types [38]. In the open-label extension trial that fol-
lowed, Wilcox et al. also demonstrated that renal function,
as measured by mean serum creatinine and estimated
GFR which was normal at baseline, remained normal over
30–36 months of treatment with agalsidase beta [32]. Of
note, only 10 patients in this trial had estimated GFR
values below 90 ml/min/1.73 m2 before treatment and renal
function was either stabilized or improved in seven of this
group by the end of the study. Furthermore, as in the study
by Schiffmann et al., there is no information in this study on
whether patients were receiving standard nephroprotective
measures (ACE inhibitors and/or ARBs) during this study.
Following publication of the baseline characteristics of
366 patients registered in FOS, an outcomes database for
patients with Fabry disease who are receiving, or may
receive, ERT with agalsidase alfa [8], Beck et al. assessed
the overall effects of 12 and 24 months of agalsidase alfa
treatment [39]. Renal disease (GFR < 90 ml/min/1.73/m2
and/or proteinuria) was present in 84% (n= 274) of the pa-
tients, for whom data were available. No data are presented
on the use of ACE inhibitors or ARBs in these patients.
Renal function was stabilized in those patients who had a
mild or moderate deterioration in renal function at base-
line (GFR between 60 and 90 ml/min/1.73/m2 or 30 and
60 ml/min/1.73/m2, respectively) following 1 and 2 years
of ERT (no data were reported for proteinuria). This should
be interpreted in the context of the rapid decline in GFR
(by 12 ml/min/year) that occurs in untreated patients with
CRI [9]. In the study by Branton et al. (2002), 18 out of
105 received an angiotensin agonist at any time. ERT with
agalsidase alfa may thus help to arrest the progression to
irreversible kidney failure in patients with mild or mod-
erate Fabry nephropathy according to data from 2 years
of treatment, but a longer follow-up is needed to evalu-
ate the long-term benefit on GFR. Interestingly, pancreatic
transplantation can reverse the glomerulosclerosis seen in
diabetic nephropathy in patients with type I diabetes, but
this requires more than 5 years of normoglycaemia [40].
Recently, Schwarting et al. reported a longitudinal anal-
ysis of data from FOS, on the progression of renal dysfunc-
tion in 201 patients with Fabry disease treated with agalsi-
dase alfa [41]. Among this population, data were available
from 1 year before treatment, at the start of treatment and
1 year after starting treatment in 20 patients (12 with a
baseline GFR of 60–89 ml/min/1.73 m2; 8 with a baseline
GFR of 30–59 ml/min/1.73 m2), and 2 years after starting
treatment in 13 patients of this group (8 with a baseline
GFR of 60–89 ml/min/1.73 m2; 5 with a baseline GFR of
30–59 ml/min/1.73 m2).
The results of the analysis revealed that the statistically
significant (P < 0.05) decline in renal function, observed
over the year prior to commencing ERT in patients with
a GFR of 60–89 ml/min/1.73 m2 at baseline, was halted
after 1 year of treatment with agalsidase alfa. Furthermore,
Fig. 2. (A) Change in estimated glomerular filtration rate (eGFR) in 20
patients before and 1 year after the initiation of enzyme replacement
therapy (ERT) with agalsidase alfa. eGFR 1 year before treatment, at
baseline and 1 year after the start of ERT in 12 patientswith amean baseline
GFR of 60–89 ml/min/1.73 m2 (top) and 8 patients with a mean eGFR
of 30–59 ml/min/1.73 m2 (bottom). (B) Change in eGFR in 13 patients
before and during 2 years after the initiation of ERT with agalsidase alfa.
eGFR 1 year before treatment, at baseline and 1 and 2 years after the start
of ERT in 8 patients with a mean baseline GFR of 60–89 ml/min/1.73 m2
(top) and 5 patients with a mean eGFR of 30–59ml/min/1.73 m2 (bottom).
Data are shown as mean (dot), median (rule) and 10th, 25th, 75th and 90th
percentiles (box and whiskers). Adapted with permission from Schwarting
et al. [41], courtesy of Dustri–Verlag.
renal function remained stable in patients with both mild
and moderate renal disease at baseline treated with agal-
sidase alfa for 2 years (Figure 2). Analysis of proteinuria
before and after ERT showed inconsistent findings with
some patients showing an increase and others a decrease.
Persistence of significant proteinuria (≥1 g/day) is a well-
known factor in the progression of CRI, whatever the
aetiology of the nephropathy [11,12]. Of the 20 patients
followed for 2 years, 5 used ACE inhibitors or ARBs at
baseline, another 5 used these drugs at any time and the
information was missing for 10 patients. A multivariate
analysis on data collected from 201 patients with serum
creatinine levels below 2 mg/dl (<180 mmol/l) revealed
a negative correlation between serum creatinine and time
on agalsidase alfa (P < 0.05), further supporting the
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conclusion that agalsidase alfa may prevent deterioration
of renal function in patients with Fabry disease who have
mild or moderate renal impairment [41].
In a more recent open-label extension trial, Germain
et al. reported longitudinal renal data in 58 patients
(56 male) with Fabry disease with normal baseline GFR,
receiving agalsidase beta for up to 54 months [42]. They
showed that median serum creatinine and estimated GFR
remained stable (normal) at month 54 in the 41 patients
for whom data were available. Renal disease progressed in
only six patients (decline in estimated GFR ranging from
−3.5 to −12.1 ml/min per 1.73 m2/year), four of whom
were over 40 years of age and had significant proteinuria
and evidence of sclerotic glomeruli at baseline. Five of this
group were receiving ACE inhibitors/ARBs during the trial
(a further 18 patients also received ACE inhibitors/ARSs
over the study). Subgroup analyses revealed that high pro-
teinuria or glomerulosclerosis at baseline contributed to
the rate of decline in estimated GFR. So the effect of
ERT combined with ACE inhibitors/ARBs on proteinuria
in Fabry disease is not clear. In addition, the study by
Germain et al. showed that Gb3 was cleared (as indicated
by a score of zero) from renal interstitial capillary en-
dothelial cells in 47 out of 49 patients after 6 months of
treatment, and in 8 out of 8 patients after 54 months of
treatment. In the available small samples (range, n = 5–8),
total clearance of Gb3 was also reported in the distal convo-
luted tubules/collecting ducts, glomerular endothelial cells,
mesangial cells and non-capillary cells of the kidney; how-
ever, clearance was not complete in the interstitial cells and
non-capillary smooth muscle. Taken together, these data
suggest that early and continued intervention with agal-
sidase beta can preserve renal function in patients with
normal renal function (and without significant proteinuria
or severe glomerulosclerosis) at the start of treatment.
A recent study investigating the agressive use of ACE
inhibitors/ARBs in patients with Fabry disease showed
that proteinuria was reduced by this therapy and that this
effect was maintained during ERT [43]. Although there was
an initial decline in estimated GFR after the introduction of
ACE inhibitors/ARBs (which was significant for those with
stage 3 or 4 kidney disease at baseline and probably due to
lowering of blood pressure), following the start of ERT,
renal function as measured by estimated GFR remained
stable. The average progression rate of estimated GFR
during treatment with agalsidase beta (mean, 30.3 months;
range, 16–43 months) was 1.18 ± 2.78 ml/min per 1.73 m2
per year in patients with stage 1 or 2 kidney disease and
−0.23 ± 1.12 ml/min per 1.73 m2 per year in patients with
stage 3 or 4 kidney disease at baseline. Although this study
did not include a control group receiving ERT alone, these
data support the combined use of ACE inhibitors/ARBs and
ERT in the treatment of renal disease in patients with Fabry
disease.
Banikazemi et al. studied the effects of ERT in 51 patients
with advanced Fabry disease (defined as having serum cre-
atinine measurements between 106 µmol/l and 265 µmol/l
or an estimated creatinine clearance<80 ml/min) receiving
agalsidase beta every 2 weeks for up to 35 months [44]. The
results of the study showed that ERT was able to slow pro-
gression to the composite clinical outcome (defined as any
clinical event) of renal, cardiac and cerebrovascular com-
plications and death compared with placebo (n = 31), even
in patients with overt kidney dysfunction. This indicates
that progression to severe manifestations was slowed. Nev-
ertheless, the authors stress that they feel that therapeutic
intervention before the onset of irreversible organ damage
is important.
An open-label study of treatment with agalsidase beta
in 25 patients (mean age, 41 years) with severe symptoms
and organ manifestations (19 men, 6 women; mean age,
30 years) presented data on renal function after a mean
treatment time of 23 ± 8 months in 20 patients (three with
functioning kidney grafts) [45]. These authors reported
clear differences in the response to ERT depending on
the baseline characteristics of the patients. While GFR
appeared to be stabilized by ERT in patients with normal
renal function at baseline (GFR > 90 ml/min/1.73 m2),
GFR was not stabilized (but the rate of progression was
reduced compared with historical cases) in those patients
with impaired renal function at baseline (mean GFR, 71 ±
17 ml/min/1.73 m2), suggesting that there is a point of
no return where kidney damage is irreversible and CRI
progresses, despite ERT.
A recent study by Schiffman et al. provides evidence that
it may be possible to reverse renal impairment by increas-
ing the dose and frequency of infusions [46]. In this study,
weekly infusions of 0.2 mg/kg agalsidase alfa were given
to a subgroup of 11 adult male patients, in whom there
was a continuing decline in renal function (estimated GFR
decline > 5 ml/min per 1.73 m2/year) despite 2–4 years
of conventional agalsidase alfa therapy (0.2 mg/kg EOW).
After switching to weekly infusions, there was a slowing
in the rate of decline of estimated GFR in six patients and
an improvement in three patients. Analysis confirmed that
the main factor responsible for this was weekly infusions of
agalsidase alfa, with a weaker contribution from the con-
comitant use of ACE inhibitors/ARBs. Of note, although
the three patients for whom estimated GFR improved had
low proteinuria upon switching to the weekly dose, five of
the seven patients with baseline proteinuria in excess of
1000 mg/24 h showed a substantial slowing of the loss of
GFR after switching. These data suggest that for a certain
subgroup of patients, an increased dose or frequency of
infusion could be beneficial. However, caution is needed
before considering a switch from agalsidase alfa to agal-
sidase beta in such patients, as data from the study by
Germain, discussed earlier, suggest a significant loss of
GFR despite a dose of 1.0 mg/kg of agalsidase beta in some
patients with normal baseline GFR who had proteinuria or
glomerulosclerosis [42]. There is clearly a need for further
prospective studies in which the risk factors for progressive
CRI in patients with Fabry disease are better defined.
It is interesting to note that an autopsy study of a
patient who had been treated with agalsidase beta for
2.5 years, showed continued tissue Gb3 storage despite
long-term ERT [47,48]. Gb3 immunostaining was detected
in the cell membrane and cytoplasm of endothelial cells,
even in the absence of lysosomal inclusions. This illustrates
that Gb3 immunoreactivity remains in cells and tissues even
after years of ERT and highlights how much we still have
to learn about the mechanisms at work in Fabry disease.
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Currently, there is only one published study of the effects
of ERT on renal function in children [17]. A recent 6-month
open-label study of treatmentwith agalsidase alfa examined
renal function in a group of 24 children with Fabry dis-
ease (19 boys, 5 girls) with, on average, normal renal func-
tion at baseline (mean estimated GFR, 121 ± 5.0 ml/min/
1.73 m2) and found that renal function remained normal
after 6 months of treatment (mean estimated GFR, 116 ±
3.9 ml/min/1.73 m2). Interestingly, in a subset of seven pa-
tients who had hyperfiltration at baseline, estimated GFR
came back to within the normal reference range following
ERT. Only one patient, who had gross proteinuria at base-
line, was receiving an ACE inhibitor. Further studies of
longer-term administration of ERT in children are needed
to evaluate whether the progressive decline in renal func-
tion that is characteristic of Fabry disease can be prevented
by treatment.
A recent study has investigated the normal distribution
of α-galactosidase A in renal cells and the manner in which
recombinant enzyme is taken up into cells. In the normal
human kidney, α-galactosidase A is found in virtually all
tubular cells and interstitial cells but not renal endothelial
cells and podocytes. In mice with Fabry disease, uptake of
recombinant α-galactosidase A occurs in podocytes, prox-
imal tubules and interstitial cells [49], but not in vascular
endothelial cells. A potential explanation for the clearance
is a rapid turnover of renal endothelial cells, which has been
demonstrated, at least for the capillary endothelial cells
[24], possibly combined with lower circulating amounts of
Gb3 as a consequence of ERT [38].
Effects of ERT in patients receiving renal replacement
therapy
Data from the USA and Europe have shown that patients
with Fabry-related ESRD who are receiving dialysis have
a lower survival rate than non-diabetic controls [18,50],
highlighting the requirement for ERT in these patients. In
an open-label prospective study of the effects of agalsidase
beta in nine patients receiving dialysis (n = 6 haemodialy-
sis, n = 3 peritoneal dialysis), treatment was well tolerated
and associated with an improvement in extrarenal symp-
toms and slower progression of left ventricular hypertrophy
[51]. That the beneficial effects of ERT are apparent in
other organ systems in patients receiving dialysis suggests
that these patients should be treated with ERT.
Home infusion
In the long-term study by Schiffmann et al., ERT with agal-
sidase alfa was well tolerated [31]. The relatively low level
of infusion reactions allowed patients to make the transition
to home infusion regimens. As ERT is a life-long treatment,
being able to use it at home for 40 min one evening every
2 weeks offers considerably less disruption to a patient’s
life than having to travel to receive treatment in hospital;
this may in itself enhance compliance. Milligan et al., in a
questionnaire survey of 20 patients receiving ERT for Fabry
disease, discovered that 95% preferred home-based therapy
because it was more comfortable, less stressful, more
effective and had less impact on family life than hospital-
based treatment [52]. Linthorst et al. also reported that
home treatment with agalsidase alfa and agalsidase beta,
0.2 mg/kg was feasible, safe and reduced both the burden
related to chronic i.v. therapy and healthcare costs [53].
However, home use of agalsidase beta at its recommended
dose of 1.0 mg/kg was not reported.
The importance of follow-up studies
The relatively low incidence of Fabry disease means that
recruitment of patients into randomized controlled clinical
trials is problematic for ethical reasons, particularly given
the heterogeneity and progressive nature of this disorder.
However, it is important to carry out long-term follow-up
studies to assess the long-term efficacy and safety of ERT
and to gather information on the natural history of this dis-
order. The systematic collection of clinical data from treat-
ment centres worldwide—as in observational studies such
as FOS and the Fabry Registry—allows large amounts of
information to be collated over a long period. The relatively
broad inclusion criteria, including coexisting illnesses and
variations in disease severity, often mean that patients
enrolled in these studies are representative of the patient
population as a whole. Furthermore, the centralization of
data from participating centres worldwide allows compar-
ison of clinical practices and efficacy data in different re-
gions as well as extending our experience of treating pa-
tients from a range of backgrounds. As such, the evidence
contained within these outcome databases may contribute
to clinical decision making and promote standardization
of clinical practices to ensure that all patients with Fabry
disease receive the required standard of care.
Finally, in view of the multisystemic nature of Fabry
disease, it is important that patients with Fabry disease
receive integrated follow-up from the appropriate special-
ists, to ensure that they receive treatment in a timely and
appropriate manner and to ensure that the standard of their
care is high.
Conclusions
Fabry nephropathy is characterized by different levels of
disease and a rate of progression of CRI very similar to
diabetic nephropathy. According to the experience gained
with diabetic nephropathy, renoprotective measures should
be introduced as soon as hyperfiltration and/or microalbu-
minuria are detected. Both enzymes have been shown to
be effective in halting the progression of renal manifesta-
tions of Fabry disease in patients with mild or moderate
Fabry nephropathy and in slowing the progression of CRI
in patients with advanced CRI. Significant proteinuria and
marked glomerulosclerosis at baseline in patients with nor-
mal GFR are the best predictors of progression of Fabry
nephropathy, despite ERT. From the 5-year follow-up of
ERT, we have learned that ERT and nephroprotective mea-
sures should be introduced as soon as possible in male pa-
tients with Fabry disease, i.e. during infancy/adolescence
before organ damage becomes irreversible. As there is no
accepted biomarker for evaluating the response to ERT
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in Fabry disease, ongoing surveillance studies, with large
numbers of patients and comprehensive data collection and
analysis, should help to determine the long-term effects of
these enzymes on morbidity and mortality in patients with
Fabry disease.
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